{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T06:49:19Z","timestamp":1791096559396,"version":"4.1.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2008,3,25]],"date-time":"2008-03-25T00:00:00Z","timestamp":1206403200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Med Oncol"],"published-print":{"date-parts":[[2008,12]]},"DOI":"10.1007\/s12032-008-9058-y","type":"journal-article","created":{"date-parts":[[2008,3,24]],"date-time":"2008-03-24T17:35:31Z","timestamp":1206380131000},"page":"431-436","source":"Crossref","is-referenced-by-count":41,"title":["Circulating levels of vascular endothelial growth factor (VEGF), matrix metalloproteinase-3 (MMP-3), and BCL-2 in malignant melanoma"],"prefix":"10.1007","volume":"25","author":[{"given":"Faruk","family":"Tas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Derya","family":"Duranyildiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hilal","family":"Oguz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hakan","family":"Camlica","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vildan","family":"Yasasever","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erkan","family":"Topuz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2008,3,25]]},"reference":[{"key":"9058_CR1","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1200\/JCO.2001.19.4.1207","volume":"19","author":"RT Poon","year":"2001","unstructured":"Poon RT, Fan ST, Wong J. Clinical implications of circulating angiogenic factors in cancer patients. J Clin Oncol. 2001;19:1207\u201325.","journal-title":"J Clin Oncol."},{"key":"9058_CR2","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1200\/JCO.2005.06.081","volume":"23","author":"DJ Hicklin","year":"2005","unstructured":"Hicklin DJ, Ellis LM. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol. 2005;23:1011\u201327.","journal-title":"J Clin Oncol."},{"key":"9058_CR3","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1038\/bjc.1997.486","volume":"76","author":"P Salven","year":"1997","unstructured":"Salven P, Heikkila P, Joensuu H. Enhanced expression of vascular endothelial growth factor in metastatic melanoma. Br J Cancer. 1997;76:930\u20134.","journal-title":"Br J Cancer."},{"key":"9058_CR4","first-page":"172","volume":"56","author":"KPM Claffey","year":"1996","unstructured":"Claffey KPM, et al. Expression of vascular permeability factor\/vascular endothelial growth factor by melanoma cells increases tumor growth, angiogenesis, and experimental metastasis. Cancer Res. 1996;56:172\u201381.","journal-title":"Cancer Res."},{"issue":"9","key":"9058_CR5","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1002\/cncr.10888","volume":"95","author":"O Simonetti","year":"2002","unstructured":"Simonetti O, et al. Immunohistochemical expression of vascular endothelial growth factor, matrix metalloproteinase 2, and matrix metalloproteinase 9 in cutaneous melanocytic lesions. Cancer. 2002;95(9):1963\u201370.","journal-title":"Cancer."},{"key":"9058_CR6","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/S0304-3835(97)00499-0","volume":"125","author":"J Viac","year":"1998","unstructured":"Viac J, Schmitt D, Claudy A. Circulating vascular endothelial growth factor (VEGF) is not a prognostic indicator in malignant melanoma. Cancer Lett. 1998;125:35\u20138.","journal-title":"Cancer Lett."},{"key":"9058_CR7","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1006\/cyto.1999.0566","volume":"12","author":"P Redondo","year":"2000","unstructured":"Redondo P, Bandres E, Solano T, Okroujnov I, Garcia-Foncillas J. Vascular endothelial growth factor (VEGF) and melanoma. N-Acetylcysteine downregulates VEGF production in vitro. Cytokine. 2000;12:374\u20138.","journal-title":"Cytokine."},{"key":"9058_CR8","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1200\/JCO.2001.19.2.577","volume":"19","author":"S Ugurel","year":"2001","unstructured":"Ugurel S, Rappl G, Tilgen W, Reinhold U. Increased serum concentration of angiogenic factors in malignant melanoma patients correlates with tumor progression and survival. J Clin Oncol. 2001;19:577\u201383.","journal-title":"J Clin Oncol."},{"key":"9058_CR9","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1067\/S0190-9622(03)00921-6","volume":"49","author":"P Redondo","year":"2003","unstructured":"Redondo P, et al. Immunologic escape and angiogenesis in human malignant melanoma. J Am Acad Dermatol. 2003;49:255\u201363.","journal-title":"J Am Acad Dermatol."},{"key":"9058_CR10","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1111\/j.1365-2133.2005.06507.x","volume":"152","author":"F Pelletier","year":"2005","unstructured":"Pelletier F, et al. Circulating vascular endothelial growth factor in cutaneous malignant melanoma. Br J Dermatol. 2005;152:685\u20139.","journal-title":"Br J Dermatol."},{"key":"9058_CR11","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1093\/jnci\/89.17.1260","volume":"89","author":"AF Chambers","year":"1997","unstructured":"Chambers AF, Matrisian LM. Changing views of the role of matrix metalloproteinases in metastasis. Natl Cancer Inst. 1997;89:1260\u201370.","journal-title":"Natl Cancer Inst."},{"key":"9058_CR12","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/S1357-4310(00)01686-5","volume":"6","author":"LJ McCawley","year":"2000","unstructured":"McCawley LJ, Matrisian LM. Matrix metalloproteinases: multifunctional contributors to tumor progression. Mol Med Today. 2000;6:149\u201356.","journal-title":"Mol Med Today."},{"key":"9058_CR13","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1023\/A:1023889805133","volume":"5","author":"MF Burbridge","year":"2002","unstructured":"Burbridge MF, et al. The role of the matrix metalloproteinases during in vitro vessel formation. Angiogenesis. 2002;5:215\u201326.","journal-title":"Angiogenesis."},{"key":"9058_CR14","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S0002-9440(10)65284-4","volume":"154","author":"J N\u00f6r","year":"1999","unstructured":"N\u00f6r J, Christensen J, Mooney DJ, Polverini PJ. Vascular endothelial growth factor (VEGF)-mediated angiogenesis is associated with enhanced endothelial cell survival and induction of bcl-2 expression. Am J Pathol. 1999;154:375\u201384.","journal-title":"Am J Pathol."},{"key":"9058_CR15","first-page":"2183","volume":"61","author":"JE N\u00f6r","year":"2001","unstructured":"N\u00f6r JE, et al. Up-regulation of Bcl-2 in microvascular endothelial cells enhances intratumoral angiogenesis and accelerates tumor growth. Cancer Res. 2001;61:2183\u20138.","journal-title":"Cancer Res."},{"key":"9058_CR16","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1023\/A:1009679307513","volume":"5","author":"W Liu","year":"2000","unstructured":"Liu W, et al. Endothelial cell survival and apoptosis in the tumor vasculature. Apoptosis. 2000;5:323\u20138.","journal-title":"Apoptosis."},{"key":"9058_CR17","doi-asserted-by":"crossref","first-page":"13313","DOI":"10.1074\/jbc.273.21.13313","volume":"273","author":"HP Gerber","year":"1998","unstructured":"Gerber HP, Dixit V, Ferrara N. Vascular endothelial growth factor induces expression of the antiapoptotic proteins Bcl-2 and A1 in vascular endothelial cells. J Biol Chem. 1998;273:13313\u20136.","journal-title":"J Biol Chem."},{"key":"9058_CR18","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1006\/bbrc.1999.1589","volume":"264","author":"J Tran","year":"1999","unstructured":"Tran J, et al. Marked induction of the IAP family antiapoptotic proteins survivin and XIAP by VEGF in vascular endothelial cells. Biochem Biophys Res Commun. 1999;264:781\u20138.","journal-title":"Biochem Biophys Res Commun."},{"key":"9058_CR19","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1096\/fj.02-0122fje","volume":"16","author":"A Iervolino","year":"2002","unstructured":"Iervolino A, et al. Bcl-2 overexpression in human melanoma cells increases angiogenesis through VEGF mRNA stabilization and HIF-1-mediated transcriptional activity. FASEB J. 2002;16:1453\u20135.","journal-title":"FASEB J."},{"key":"9058_CR20","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1096\/fj.01-0819com","volume":"16","author":"I. Segura","year":"2002","unstructured":"Segura I. Inhibition of programmed cell death impairs in vitro vascular-like structure formation and reduces in vivo angiogenesis. FASEB J. 2002;16:833\u201341.","journal-title":"FASEB J."},{"key":"9058_CR21","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1097\/00008390-200412000-00017","volume":"14","author":"F Tas","year":"2004","unstructured":"Tas F, et al. Serum bcl-2 and survivin levels in melanoma. Melanoma Res. 2004;14:543\u20136.","journal-title":"Melanoma Res."},{"key":"9058_CR22","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1385\/MO:22:1:039","volume":"22","author":"F Tas","year":"2005","unstructured":"Tas F, et al. Serum matrix metalloproteinase-3 and tissue inhibitor of metalloproteinase-1 in patients with malignant melanoma. Med Oncol. 2005;22:39\u201344.","journal-title":"Med Oncol."},{"key":"9058_CR23","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1038\/sj.gene.6363851","volume":"3","author":"WM Howell","year":"2002","unstructured":"Howell WM, Bateman AC, Turner SJ, Collins A, Theaker JM. Influence of vascular endothelial growth factor single nucleotide polymorphisms on tumour development in cutaneous malignant melanoma. Genes Immun. 2002;3:229\u201332.","journal-title":"Genes Immun."},{"key":"9058_CR24","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1007\/s004280050443","volume":"435","author":"RA Walker","year":"1999","unstructured":"Walker RA, Woolley DE. Immunolocalisation studies of matrix metallproteinase-1, -2, and -3 in human melanoma. Virchows Arch. 1999;435:574\u20139.","journal-title":"Virchows Arch."},{"key":"9058_CR25","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1038\/sj.bjc.6690763","volume":"81","author":"UB Hofmann","year":"1999","unstructured":"Hofmann UB, et al. Matrix metalloproteinases in human melanoma cell lines and xenografts: increased expression of activated matrix metalloproteinase-2 (MMP-2) correlates with melanoma progression. Br J Cancer. 1999;81:774\u201382.","journal-title":"Br J Cancer."},{"key":"9058_CR26","first-page":"721","volume":"22","author":"JB Meric","year":"2003","unstructured":"Meric JB, et al. Relevance of matrix metalloproteinase (MMP) plasma levels in malignant melanoma (MMM). Proc Am Soc Clin Oncol. 2003;22:721, Abstract 2899.","journal-title":"Proc Am Soc Clin Oncol."},{"key":"9058_CR27","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/s004030050479","volume":"292","author":"U Leiter","year":"2000","unstructured":"Leiter U, Schmid RM, Kaskel P, Peter RU, Krahn G. Antiapoptotic bcl-2 and bcl-XL in advanced malignant melanoma. Arch Dermatol Res. 2000;292:225\u201332.","journal-title":"Arch Dermatol Res."},{"key":"9058_CR28","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1200\/JCO.2003.08.066","volume":"21","author":"A Gradilone","year":"2003","unstructured":"Gradilone A, et al. Survivin, bcl-2, bax, and bcl-X gene expression in sentinal lymph nodes from melanoma patients. J Clin Oncol. 2003;21:306\u201312.","journal-title":"J Clin Oncol."}],"container-title":["Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-008-9058-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12032-008-9058-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-008-9058-y","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,2]],"date-time":"2019-06-02T02:22:34Z","timestamp":1559442154000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12032-008-9058-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,3,25]]},"references-count":28,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2008,12]]}},"alternative-id":["9058"],"URL":"https:\/\/doi.org\/10.1007\/s12032-008-9058-y","relation":{},"ISSN":["1357-0560","1559-131X"],"issn-type":[{"value":"1357-0560","type":"print"},{"value":"1559-131X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,3,25]]}}}